1st Patient Dosed in Trial of UB-312, Vaccine Against Protein Clumps

1st Patient Dosed in Trial of UB-312, Vaccine Against Protein Clumps

316207

1st Patient Dosed in Trial of UB-312, Vaccine Against Protein Clumps

A first patient with Parkinson’s disease has been dosed with UB-312, Vaxxinity’s experimental vaccine therapy targeting alpha-synuclein, after treatment safety and tolerability was seen in healthy volunteers in a clinical trial. This marks the beginning of Part B in the Phase 1 trial (NCT04075318), which is enrolling up to 20 people with early to mild or moderate Parkinson’s at its site in the Netherlands. More information on enrollment and contacts can be found here. “We are…

You must be logged in to read/download the full post.